JP2021523139A5 - - Google Patents
Info
- Publication number
- JP2021523139A5 JP2021523139A5 JP2020562598A JP2020562598A JP2021523139A5 JP 2021523139 A5 JP2021523139 A5 JP 2021523139A5 JP 2020562598 A JP2020562598 A JP 2020562598A JP 2020562598 A JP2020562598 A JP 2020562598A JP 2021523139 A5 JP2021523139 A5 JP 2021523139A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- polypeptide
- soluble
- signal sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668293P | 2018-05-08 | 2018-05-08 | |
| US62/668,293 | 2018-05-08 | ||
| PCT/US2019/031049 WO2019217373A1 (en) | 2018-05-08 | 2019-05-07 | Compositions and methods for reducing progression of nephrolithiasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523139A JP2021523139A (ja) | 2021-09-02 |
| JP2021523139A5 true JP2021523139A5 (https=) | 2022-05-13 |
Family
ID=68466827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562598A Pending JP2021523139A (ja) | 2018-05-08 | 2019-05-07 | 腎石症の進行を遅らせるための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12157903B2 (https=) |
| EP (1) | EP3790628A4 (https=) |
| JP (1) | JP2021523139A (https=) |
| AU (1) | AU2019267545A1 (https=) |
| CA (1) | CA3099266A1 (https=) |
| WO (1) | WO2019217373A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| CN120383683A (zh) | 2018-08-31 | 2025-07-29 | 耶鲁大学 | Enpp1多肽及其使用方法 |
| KR20230048480A (ko) * | 2020-05-27 | 2023-04-11 | 이노자임 파마, 인코포레이티드 | 말초 동맥 질환을 치료하기 위한 조성물 및 방법 |
| KR20230047334A (ko) * | 2020-05-27 | 2023-04-07 | 이노자임 파마, 인코포레이티드 | 혈관 평활근 세포 증식을 억제하기 위한 조성물 및 방법 |
| WO2021252549A1 (en) * | 2020-06-09 | 2021-12-16 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
| CA3246877A1 (en) * | 2022-03-30 | 2023-10-05 | Yale University | METHOD AND COMPOSITIONS FOR THE TREATMENT, ALLEVIATION AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) |
| KR102748577B1 (ko) * | 2022-07-19 | 2025-01-06 | 가천대학교 산학협력단 | 바이오마커 enpp7의 당뇨병의 진단 및 치료 용도 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04292169A (ja) | 1991-03-19 | 1992-10-16 | Sekisui Chem Co Ltd | ハイブリッド型人工膵臓 |
| WO1995019570A1 (en) | 1994-01-14 | 1995-07-20 | Genentech, Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
| US6521645B2 (en) | 2000-11-20 | 2003-02-18 | The University Of Kansas Medical Center | Methods for the treatment and prevention of urinary stone disease |
| JP4200100B2 (ja) | 2001-11-07 | 2008-12-24 | アジェンシス，インコーポレイテッド | 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質 |
| US9055984B2 (en) | 2004-04-21 | 2015-06-16 | DePuy Synthes Products, Inc. | Sternal reconstruction system |
| JP5199077B2 (ja) * | 2005-06-10 | 2013-05-15 | アルタス ファーマシューティカルズ インコーポレイテッド | シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法 |
| WO2008105911A2 (en) | 2006-08-02 | 2008-09-04 | Altus Pharmaceuticals Inc. | Crystallized oxalate decarboxylase and methods of use |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| EA201301082A1 (ru) | 2011-03-29 | 2014-01-30 | Бета-Селл Нв | Способ изготовления инкапсулированных терапевтических продуктов и их применение |
| WO2014126965A2 (en) | 2013-02-13 | 2014-08-21 | Yale University | Compositions and methods for treating pathological calcification and ossification |
| EP2970940B1 (en) * | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| BR112016006071B1 (pt) | 2013-09-19 | 2021-12-28 | Universitãtsspital Basel | Enxerto vascular artificial e método para a produção de um enxerto vascular artificial |
| EP3967755B1 (en) * | 2014-12-19 | 2024-03-27 | Inozyme Pharma, Inc. | Soluble npp1 for use in a method for treating pseudoxanthoma elasticum |
| EP4414028A3 (en) | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| JP6543119B2 (ja) | 2015-07-10 | 2019-07-10 | 有限会社Ptmc研究所 | ステントグラフト |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| CA3032467A1 (en) * | 2016-08-05 | 2018-02-08 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| US20180085492A1 (en) | 2016-09-29 | 2018-03-29 | Northwestern University | Antioxidant scaffolds for beta cell delivery |
-
2019
- 2019-05-07 AU AU2019267545A patent/AU2019267545A1/en not_active Abandoned
- 2019-05-07 US US17/052,199 patent/US12157903B2/en active Active
- 2019-05-07 CA CA3099266A patent/CA3099266A1/en active Pending
- 2019-05-07 WO PCT/US2019/031049 patent/WO2019217373A1/en not_active Ceased
- 2019-05-07 EP EP19798912.2A patent/EP3790628A4/en not_active Withdrawn
- 2019-05-07 JP JP2020562598A patent/JP2021523139A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523139A5 (https=) | ||
| ES2537974T3 (es) | Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para el tratamiento de la encefalopatía hepática | |
| JP2024503265A5 (https=) | ||
| JP2002544174A5 (https=) | ||
| ES2265470T3 (es) | Soluciones farmaceuticas inyectables que contienen paracetamol y combinaciones de paracetamol con otras sustancias activas. | |
| CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
| BR9912694A (pt) | Composto para preparar medicamento de administração pulmonar | |
| O’Laughlin et al. | Does aspirin prolong bleeding from gastric biopsies in man? | |
| IT9020944A1 (it) | Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria | |
| KR100347631B1 (ko) | 해열진통배합제 | |
| CN107206049A (zh) | 治疗患1型肝肾综合征的患者的方法 | |
| ES2604254T3 (es) | Combinaciones de flurbiprofeno de liberación controlada y relajante muscular | |
| JP2746832B2 (ja) | 眼局所抗アレルギー剤 | |
| JPH05148139A (ja) | イブプロフエン含有解熱鎮痛剤 | |
| JP4175801B2 (ja) | 消炎鎮痛点眼剤 | |
| ES2529432T3 (es) | Composición farmacéutica anticonvulsiva transnasal | |
| JP7787823B2 (ja) | Ｃｃｒ９阻害剤及び抗ｉｌ－２３遮断抗体を使用する炎症性腸疾患を治療するための組成物及び方法 | |
| ES2337663T3 (es) | Compuestos peptidicos que se unen selectivamente a p-selectina. | |
| JPH08295637A (ja) | 口腔部局所投与剤 | |
| JP2008542290A (ja) | 皮膚狼瘡の治療又は予防のための４−［（シクロプロパンカルボニルアミノ）メチル］−２−（２，６−ジオキソピペリジン−３−イル）イソインドール−１，３−ジオンの使用方法及び組成物 | |
| ES2970909T3 (es) | Composición farmacéutica para administración nasal que comprende rifampicinas para el tratamiento de la demencia | |
| JP2000507207A (ja) | 複合注射剤 | |
| ES2304955T3 (es) | Medicamentos contra la insuficiencia renal. | |
| KR870009716A (ko) | 클로르페니라민 제형 | |
| ES3014714T3 (en) | Use of ambrisentan for the treatment of portal hypertension |